Abstracts Archive - Page 906 of 2425 - ACR Meeting Abstracts

Abstract Number: 2215 • 2019 ACR/ARP Annual Meeting
Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab
David Dempster¹, Peter Butler ², Mathias Bostrom ³, Jeri Nieves ¹, Hua Zhou ⁴, Li Chen ², Nicola Pannacciulli ², Rachel Wagman ² and Felicia Cosman ¹, ¹Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Hospital for Special Surgery, New York, NY, ⁴Helen Hayes Hospital, West Haverstraw, NY
Background/Purpose: Denosumab (DMAb) is a potent antiresorptive agent, but findings in non-human primates suggest that modeling-based bone formation (MBBF) may persist despite DMAb treatment (Ominsky…
Abstract Number: 2216 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
KEN NAKASEKO¹, ¹Department of Orthopaedic Surgery and Rheumatology Kuwana City Medical Center, kuwana mie, Japan
Background/Purpose: Bone mineral density (BMD) is used for the diagnosis of osteoporosis, predicting future fracture risk, and monitoring osteoporosis treatment. Osteoporosis is defined as BMD…
Abstract Number: 2217 • 2019 ACR/ARP Annual Meeting
DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids
Sima Terebelo¹, Madina Abduraimova ¹, Latoya Freeman-Beman ¹, Naureen Kabani ², Joshy Pathiparampil ¹, Olga Dvorkina ² and Ellen M Ginzler ³, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, ³State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Osteoporosis (OP) is a problem in the aging population. Patients with autoimmune disease are at increased risk for OP given their history of steroid…
Abstract Number: 2218 • 2019 ACR/ARP Annual Meeting
1,25D3 Promotes Mineralization of Osteoblasts by Activating C/EBPβ-DKK1 Axis
Sungsin Jo¹, Subin Yoon ¹, Seoung Wan Nam ², Jae-Hyuk Yang ³, Il-hoon Sung ⁴ and Tae-Hwan Kim ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, ³Department of Orthopedic Surgery, Hanyang University Medical Center, Guri Hospital,, Guri, Republic of Korea, ⁴Division of Orthopedics, Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea
Background/Purpose: 1,25-Dihydroxyvitamin D3 (1,25D3) has a positive therapeutic effect on osteoporosis by activating osteoblasts. Bone formation is a dynamic and sequential process that comprises osteoblasts…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Nancy Lane¹, Richard Weiss ², Bruce Mitlak ³, Yamei Wang ⁴, Guillermo Valenzuela ⁵ and Chad Deal ⁶, ¹University of California at Davis Medical Center, Sacramento, CA, ²Radius Health, Inc, Waltham, ³Radius Health, Inc, Waltham, MA, ⁴Radius Health, Inc, Waltham, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…
Abstract Number: 2221 • 2019 ACR/ARP Annual Meeting
Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study
Luis Seguro ¹, Rosa Pereira ², Luciana Seguro³, Valeria Caparbo ³, Monica Avila ¹, Sandrigo Mangini ¹, Iascara Campos ¹, Fabio Gaiotto ¹, Fabiana Marcondes-Braga ¹ and Fernando Bacal ¹, ¹Instituto do Coracao (InCor), HCFMUSP, Sao Paulo, ²Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo
Background/Purpose: Data on prevention of fractures after heart transplant (HTx) are controversial in the literature. Understanding the effects of HTx on bone may guide appropriate…
Abstract Number: 2222 • 2019 ACR/ARP Annual Meeting
Bone Health: An Independent Predictor of Coronary Artery Disease
Lilian Bizzocchi¹, Maria Salgado ¹, Bhavin Chokshi ¹, Navneet Kaur ¹, Oscar Mena ¹ and Michal Packman ², ¹Jacobi Medical Center, Bronx, NY, ²North Central Bronx Hospital, Bronx, NY
Background/Purpose: An association between low bone mineral density (BMD) and cardiovascular events has been shown. The calcification process observed in atherosclerosis and bone mineralization have…
Abstract Number: 2223 • 2019 ACR/ARP Annual Meeting
Attenuated Association Between Proton Pump Inhibitor Use and Fracture Risk After Consideration of Chronic Comorbidities
Liwei Wang ¹, Elizabeth Atkinson ¹, Hongfang Liu ¹ and Shreyasee Amin¹, ¹Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Proton pump inhibitors (PPI), which are often recommended in patients with rheumatic diseases due to frequent use of high risk medications such as NSAIDs…
Abstract Number: 2224 • 2019 ACR/ARP Annual Meeting
Parkinson’s Disease and Risk of Fractures : A Meta Analysis of Cohort Studies
marion louvois¹, stéphanie Ferrero ¹, Thomas Barnetche ², christian roux ¹ and Véronique Breuil ¹, ¹university of nice, nice, France, ²university of bordeaux, bordeaux, France
Background/Purpose: Parkinson's disease is a common neurodegenerative disorder in older adults. Parkinson's patients have an increase risk of falls. More over, previous studies have shown…
Abstract Number: 2225 • 2019 ACR/ARP Annual Meeting
Systematic Osteoporosis Screening in Chronic Obtructive Pulmonary Disease (Study of Correlation Between Pulmonary Functions Tests and Bone Parameters): Emphysematous Status Is Linked to Low Bone Density and Osteoporosis
Olivier Malaise¹, Cécile André ¹, Laurence Seidel ², Florence Schleich ³, Renaud Louis ³ and Michel Malaise ¹, ¹Rheumatology department, CHU and University of Liège, Liège, Belgium, ²Biostatistics department, CHU and University of Liège, Liège, Belgium, ³Pneumology department, CHU and University of Liège, Liège, Belgium
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is usually considered as a risk factor for osteoporosis. However, COPD is an heterogeneous disease with different phenotypes, based…
Abstract Number: 2226 • 2019 ACR/ARP Annual Meeting
Factors Contributing to Fracture in Pernicious Anemia Patients Presenting with Symptomatic Subacute Vertebral Compression Fractures
Michael Lovy¹, Nir Ben-Shlomo ² and Jacob Hattenbach ³, ¹Desert Oasis Healthcare, Palm Springs, CA, ²Ben-Gurion Medical School, Beer Sheva, Israel, ³College of Osteopathic Medicine of the Pacific, Pomona
Background/Purpose: Pernicious anemia (PA) has been associated with both low spine BMD and increased fracture risk in retrospective cohort studies. The cause of these observations…
Abstract Number: 2227 • 2019 ACR/ARP Annual Meeting
Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels?
Carolina Tornero¹, Victoria Navarro-Compán ², Jair Antonio Tenorio ³, Sara García ⁴, Antonio Buño ⁵, Irene Monjo ⁶, Chamaida Plasencia ⁷, Jose María Iturzaeta ⁸, Pablo Lapunzina ³, Karen Heath ³, Alejandro Balsa ⁷ and Pilar Aguado ¹, ¹Rheumatology Department. La Paz University Hospital., Madrid, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Genetics Department. La Paz University Hospital. CIBERER, Madrid, ⁴Rheumatology Department. La Paz University Hospital, Madrid, ⁵Clinical Biochemistry, La Paz University Hospital, Madrid, ⁶FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ⁸Clinical Biochemisty. La Paz University Hospital, Madrid
Background/Purpose: Hypophosphatasia (HPP) is caused by mutations in ALPL, resulting in low alkaline phosphatase (ALP) levels. The determination of ALPL mutation may not be accessible…
Abstract Number: 2228 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients
Katherine Wysham¹, Jonathan Graf ², Jane Shofer ³, Dennis Black ², James Andrews ³, Dolores Shoback ² and Patricia Katz ², ¹Veterans Health Administration Puget Sound, Seattle WA, Seattle, ²University of California, San Francisco, San Francisco, CA, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for osteoporosis (OP) and fracture. Although several OP risk factors are well-described in RA, many mechanisms…
Abstract Number: 2229 • 2019 ACR/ARP Annual Meeting
Differences in Fracture Risk Assessment (FRAX) and Osteoporosis Treatment Cutoffs with and Without Bone Mineral Density Are Greater in Anti-Cyclic Citrullinated Peptide Positive Rheumatoid Arthritis
Katherine Wysham¹, Jonathan Graf ², Mary Margaretten ², Laura Trupin ², James Andrews ³, Dolores Shoback ² and Patricia Katz ², ¹Veterans Health Administration Puget Sound, Seattle WA, Seattle, ²University of California, San Francisco, San Francisco, CA, ³University of Washington, Seattle, WA
Background/Purpose: FRAX (Fracture Risk Assessment Tool) is the most commonly used tool to estimate 10-year fracture risk. FRAX estimates are performed with and without bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].